ArticleMalaria journal2026
Adherence to 14-day primaquine treatment for radical cure of Plasmodium vivax and mixed malaria patients treated at health centers in Yilmana Densa district, Ethiopia: a community-based cross-sectional study.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimaquine is the right drug for the radical cure of malaria. The Ethiopian National malaria guideline recommends a 14-day course of primaquine for vivax and mixed malaria patients. Adherence to the full course of primaquine is crucial to achieve a radical cure. However, the recurrence of malaria is still high. Therefore, this study aimed to assess adherence status and identify factors affecting adherence to primaquine treatment among malaria patients treated at health centers in Yilmana Densa district, Ethiopia.
methodsA community-based cross-sectional study was conducted in Yilmana Densa district from December 15, 2024 to January 30, 2025. A total of 594 malaria patients were selected using systematic random sampling. Data were collected through house-to-house visits by using an interviewer-administered questionnaire and observation. Self-report, followed by a pill count, was used to ascertain adherence status. The data were entered with EpiData 4.7 and analyzed using Stata version 17. Binary logistic regression was used. Variables with a P-value < 0.25 in bivariable analysis were entered into multivariable analysis. Variables with a P-value < 0.05 were considered statistically significant.
resultsAmong the 594 study participants, 545 (91.8%) were interviewed. The overall adherence to primaquine treatment was 282 (51.7%), with a 95% confidence interval (CI) of 47.4% to 56.0%. Female sex (AOR = 1.64, 95%CI = 1.11-2.43), having knowledge that malaria can relapse (AOR = 1.69, 95%CI = 1.11-2.58), and a prior history of malaria infection (AOR = 1.67, 95%CI = 1.14-2.44) were positively associated with probably adherent. Whereas experiencing side effects was negatively associated (AOR = 0.49, 95%CI = 0.33-0.72).
conclusionsThe primaquine treatment adherence status is low in the Yilmana Densa district. Being female, having knowledge that malaria can relapse, and having a prior malaria history were positively associated with adherence. Conversely, side effect has negatively associated. Hence, health education focusing on the risk of malaria relapse shall be promoted, giving due attention to males, and counselling about the expected side effects proactively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.